Combining the HSP90 inhibitor, AT13387, with vemurafenib delays the emergence of V600E resistance in a preclinical model of BRAF mutant melanoma. Tomoko Smyth, Jon Lewis, Keisha Hearn, Neil Thompson, John Lyons, Mohammad

First Page		Document Content
Date: 2013-09-21 15:10:26 Chemistry Tyrosine kinase inhibitors Organochlorides Organofluorides Sulfonamides Vemurafenib BRAF Hsp90 Melanoma Medicine Biology Oncogenes		Combining the HSP90 inhibitor, AT13387, with vemurafenib delays the emergence of V600E resistance in a preclinical model of BRAF mutant melanoma. Tomoko Smyth, Jon Lewis, Keisha Hearn, Neil Thompson, John Lyons, Mohammad Add to Reading List Source URL: astx.com Download Document from Source Website File Size: 516,79 KB Share Document on Facebook

	03_2018_ΟΔΗΓΙΕΣ BRAF_ΜΕΛΑΝΩΜΑ_CLEAN DocID: 1tOTO - View Document
	Collection BRAF : wiki ballons n° 1.0 f6agv @ free.fr - Alain Verbrugge CONDITION DE DECOLLAGE D’UN BALLON SOLAIRE photo : f6agv DocID: 1sWxr - View Document
	Atypical Protein Kinases (aPKs) Supplemental Online Material for Manning et al (Science 298:Atypical protein kinases lack sequence similarity to the ePK domain HMM profile, but have been shown experimentally t DocID: 1qVny - View Document
	Letter pubs.acs.org/acsmedchemlett Structural Analysis of the Binding of Type I, I1/2, and II Inhibitors to Eph Tyrosine Kinases Jing Dong,*,† Hongtao Zhao,† Ting Zhou,† Dimitrios Spiliotopoulos,† Chitra Rajendra DocID: 1pvTL - View Document
	Signature® BRAF Mutations Kit The Signature® BRAF Mutations Kit is a qualitative in vitro diagnostic device to identify specific BRAF mutations in genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) colo DocID: 1lWFv - View Document